Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA

Key Points

• Jennison Associates LLC boosted its stake in Palvella by 262.4% in Q4 to 387,483 shares, representing a 3.27% ownership position worth approximately $40.56 million.
• Company insiders (Directors Elaine J. Heron and George M. Jenkins) bought shares at $125 — 2,400 and 4,000 shares respectively — lifting insider ownership to 20.50%.
• Palvella stock opened at $126.84, trades in a 12‑month range of $20.20–$151.18 with a $1.82 billion market cap, reported a -$1.08 EPS last quarter, and carries a MarketBeat consensus of "Moderate Buy" with an average target of $198.07.

Jennison Associates LLC boosted its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 262.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387,483 shares of the company's stock after purchasing an additional 280,573 shares during the quarter. Jennison Associates LLC owned 3.27% of Palvella Therapeutics worth $40,558,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PVLA. Archer Investment Corp acquired a new position in Palvella Therapeutics during the third quarter valued at approximately $28,000. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics during the third quarter valued at approximately $36,000. JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock valued at $73,000 after purchasing an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Palvella Therapeutics during the second quarter valued at approximately $85,000. Finally, BNP Paribas Financial Markets acquired a new position in Palvella Therapeutics during the second quarter valued at approximately $104,000. Institutional investors and hedge funds own 40.11% of the company's stock.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $126.84 on Friday. Palvella Therapeutics, Inc. has a twelve month low of $20.20 and a twelve month high of $151.18. The firm's 50 day moving average price is $124.68 and its two-hundred day moving average price is $101.01. The firm has a market cap of $1.82 billion, a P/E ratio of -34.19 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.13). On average, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -4.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PVLA. Wall Street Zen cut shares of Palvella Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Mizuho boosted their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. Chardan Capital boosted their price objective on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $198.07.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron acquired 2,400 shares of the business's stock in a transaction dated Friday, February 27th. The shares were acquired at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the transaction, the director directly owned 47,812 shares in the company, valued at $5,976,500. This trade represents a 5.28% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director George M. Jenkins acquired 4,000 shares of the business's stock in a transaction dated Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the transaction, the director owned 187,171 shares of the company's stock, valued at $23,396,375. This represents a 2.18% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 20.50% of the stock is currently owned by insiders.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.